This page shows the latest axicabtagene ciloleucel news and features for those working in and with pharma, biotech and healthcare.
Yescarta (axicabtagene ciloleucel) reached $175m in relapsed/refractory large B-cell lymphoma and relapsed/refractory indolent follicular lymphoma in both the US and Europe.
Kite has already seen success with its own CAR T treatments, which includes Tecartus (brexucabtagene autoleucel) and Yescarta (axicabtagene ciloleucel).
The top-line results come from the phase 3 ZUMA-7 trial, which is investigating Yescarta (axicabtagene ciloleucel) compared to standard of care (SOC) in second-line LBCL.
Specifically, Yescarta (axicabtagene ciloleucel) has been approved for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) – a form of indolent non-Hodgkin lymphoma (iNHL) – after two or ... In the ZUMA-12 trial,
Gilead/Kite’s Yescarta (axicabtagene ciloleucel) was the first FDA-approved CAR T therapy for the treatment of adult patients with relapsed or refractory LBCL, including DLBCL.
This includes Yescarta (axicabtagene ciloleucel) and Tecartus M (brexucabtagene autoleucel), which helped to grow sales by 34% to $163m in Q4 and 33% to $607m for the entire year.
More from news
Approximately 1 fully matching, plus 48 partially matching documents found.
Early signs are looking good: Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June
Kite Pharma. Daiichi Sankyo. Licence. Cellular cancer therapy axicabtagene ciloleucel (KTE-C19).
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ experience, Innovative Trials deploys “boots-on-the-ground”...